期刊文献+

加味消风散治疗吉非替尼所致皮疹临床观察 被引量:26

下载PDF
导出
摘要 目的:观察加味消风散治疗吉非替尼所致皮疹的临床疗效。方法:64例随机分为两组,治疗组32例给予加味消风散治疗,对照组32例给予氢化可的松软膏及红霉素软膏外用,观察两组的临床疗效及主观症状改善情况。结果:总有效率治疗组与对照组分别为93.75%、62.50%,两组比较差异有统计学意义(P<0.05)。结论:加味消风散治疗吉非替尼所致皮疹具有较好临床疗效。 Objective : To observe clinical therapeutic effect of JiaWei Xiaofeng Powder on Gefitinib treatment-related skirt rashes. Method: 64 cases were randomly divided into the treatment group and the control group, with 32 cases in each group. The treatment group were treated with JiaWei Xiaofeng Powder while the control groups were treated with Hydrocortisone ointment and Erythromycin ointment by external application. The clinical curative effect of two groups and the improvement of subjective symptoms was observed. Result: The effective rate of the treatment group and the control group was 93.75% and 62.50% respectively. There was significant statistical difference between the two groups (P〈0.05). Conclusion: JiaWei Xiaofeng Powder has better clinical curative effect on Gefitinib treatment-related skin rashes.
出处 《实用中医药杂志》 2017年第5期469-471,共3页 Journal of Practical Traditional Chinese Medicine
关键词 肺癌 吉非替尼 皮疹 加味消风散 Lung cancer Skin rashes JiaWei Xiaofeng Powder Gefitinib
  • 相关文献

参考文献4

二级参考文献101

  • 1钱军,秦叔逵.针对表皮生长因子受体的靶向治疗研究进展[J].中国药科大学学报,2004,35(3):285-288. 被引量:14
  • 2陈锐深.易瑞沙所致皮疹的中医药治疗[J].华夏医药,2007,2(2):99-100. 被引量:2
  • 3Mendelsohn J,Baselga J.Epidermal growth factor receptor targeting in cancer[J].Semin Oncol,2006,33(4):369-385.
  • 4Arteaga CL.The epidermal growth factor receptor:From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia[J].J Clin Oncol,2001,19(suppl 18):32S-40S.
  • 5Fox LP.Nail toxicity associated with epidermal growth factor receptor inhibitor therapy[J].J Am Acad Dermatol,2007,56(3):460-465.
  • 6Lenz HJ.Anti-EGFR mechanism of action:antitumor effect and underlying cause of adverse events[J].Oncology,2006,20(5suppl 2):5-13.
  • 7Lynch TJ,Kim ES,Eaby B,et al.Epidemal growth factor receptor inhibitor-associated cutaneous toxicities:an evolving paradigm in clinical management[J].Oncologist,2007,12(5):610-621.
  • 8Giaccone G,Herbst RS,Manegold C,et al.Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer:a phase Ⅲ trial-INTACT1[J].J Clin Oncol,2004,22(5):777-784.
  • 9Johnson JR,Cohen M,Sridhara R,et al.Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen[J].Clin Cancer Res,2005,11(18):6414-6421.
  • 10Wacker B,Nagrani T,Weinberg J,et al.Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies[J].Clin Cancer Res,2007,13(13):3913-3921.

共引文献25

同被引文献285

引证文献26

二级引证文献106

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部